|
Q1 FY2027
As of Jul 31, 2026
|
Q4 FY2026
As of Apr 30, 2026
|
Q3 FY2026
As of Jan 31, 2026
|
Q2 FY2026
As of Oct 31, 2025
|
Q1 FY2026
As of Jul 31, 2025
|
Q4 FY2025
As of Apr 30, 2025
|
Q3 FY2025
As of Jan 31, 2025
|
Q2 FY2025
As of Oct 31, 2024
|
Q1 FY2025
As of Jul 31, 2024
|
Q4 FY2024
As of Apr 30, 2024
|
Q3 FY2024
As of Jan 31, 2024
|
Q2 FY2024
As of Oct 31, 2023
|
Q1 FY2024
As of Jul 31, 2023
|
Q4 FY2023
As of Apr 30, 2023
|
Q3 FY2023
As of Jan 31, 2023
|
Q2 FY2023
As of Oct 31, 2022
|
Q1 FY2023
As of Jul 31, 2022
|
Q4 FY2022
As of Apr 30, 2022
|
Q3 FY2022
As of Jan 31, 2022
|
Q2 FY2022
As of Oct 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Marketable equity securities | ||||||||||||||||||||
| Dividends receivable | ||||||||||||||||||||
| Investment in preferred stock - QCLS - current | ||||||||||||||||||||
| Warrant asset – QCLS - current | ||||||||||||||||||||
| Convertible Note receivable – Femasys - current | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Intangibles | ||||||||||||||||||||
| Other assets: | ||||||||||||||||||||
| Intangible assets net excluding goodwill | ||||||||||||||||||||
| Investment in SG Austria | ||||||||||||||||||||
| Convertible note receivable | ||||||||||||||||||||
| Warrant asset | ||||||||||||||||||||
| Convertible note receivable – Femasys | ||||||||||||||||||||
| Investment in preferred stock – QCLS | ||||||||||||||||||||
| Warrant asset – QCLS – non current | ||||||||||||||||||||
| Convertible note receivable – Femasys - non current | ||||||||||||||||||||
| Warrant asset – Femasys | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total other assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Accrued Series C dividends | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term portion of accrued expenses | ||||||||||||||||||||
| Warrant liabilities | ||||||||||||||||||||
| Derivative liabilities | ||||||||||||||||||||
| Total other liabilities | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Convertible preferred stock | ||||||||||||||||||||
| Series B Preferred Stock | ||||||||||||||||||||
| Series C Preferred Stock | ||||||||||||||||||||
| Contingently redeemable warrants | ||||||||||||||||||||
| Total temporary equity | ||||||||||||||||||||
| Stockholders’ equity: | ||||||||||||||||||||
| Preferred stock value | ||||||||||||||||||||
| Series A Preferred Stock | ||||||||||||||||||||
| Total preferred stock value | ||||||||||||||||||||
| Common stock: authorized 200,000,000 shares, $0.0001 par value; 26,005,715 shares issued and 10,735,649 shares outstanding as of July 31, 2026 and April 30, 2026, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Treasury stock, at cost, 15,270,066 shares as of July 31, 2026, and April 30, 2026, respectively | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total Liabilities, Temporary Equity and Stockholders’ Equity | ||||||||||||||||||||
Loading...
